Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19

• Status: Recruiting
• Trial end date: 2023-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Clinical, control, double-blind, randomized trial with tenofovir disoproxyl fumarate and emtricitabine for Covid-19

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universidade Federal do Ceara
• Collaborators: Central Laboratory of Public Health of Ceará - Lacen-CE; Conselho Nacional de Desenvolvimento Científico e Tecnológico; São José Hospital for Infectious Diseases - HSJ
• Treatments: Ascorbic Acid; Emtricitabine; Tenofovir

Criteria

Inclusion Criteria:

• Patient is > 18 years old

• Patient diagnosed with COVID-19

Exclusion Criteria:

• Patient is already receiving some of the study drugs

• There is a hospitalization plan in the next 24h

• Some study treatment is contraindicated

• Patient has HIV infection

• Patient has VHB infection

• Patient lives in another city or state

• Female patient, pregnant